Associate Professor of Surgery
Director, Neurosurgical Oncology and The University of Chicago Brain Tumor
Center,
The University of Chicago
Neurosurgery, MC 3026
5841 S. Maryland Avenue
Chicago, IL 60637
Tel: (773) 834-4757
Fax: (773) 834-2608
Email:
Education
B.A.: Harvard University, Cambridge, MA
M.D.: Johns Hopkins University, Baltimore, MD
Internship: Johns Hopkins University, Baltimore, MD General Surgery
Residency: Johns Hopkins Hospital, Baltimore, MD Neurosurgery
Fellowship: Johns Hopkins University, Baltimore, MD Neurosurgical Oncology
and Immunology
• Clinical
Interests
• Complete
Bibliography
• Brain Tumor Center
• Lab Personnel
• Image Gallery:
(To view the images click on the icons below.)
High grade gliomas represent the most common primary malignant tumor of the adult central nervous system. Unfortunately, the median survival after surgical intervention alone is only six months and the addition of radiotherapy can extend this time to nine months. Given the poor prognosis of patients with malignant brain tumors, new and innovative approaches are urgently needed to make an impact on this devastating disease. Efforts aimed at developing new therapies have focused on treatment strategies that target tumor cells and spare normal cells. One such modality, gene therapy, has shown promise in the spectrum of agents utilized against malignant brain tumors. Our laboratory focuses on gene therapy, both with respect to the development of novel vectors as well as modulation of the immune response, with the ultimate aim of translating this work into a clinical trial for patients with malignant brain tumors. (read more)
Lesniak MS, and Brem H: Targeted therapy for brain tumors. Nature Reviews: Drug Delivery.3(6):499-508, 2004. (PubMed)
Hsu W, Lesniak MS, Tyler BM, and Brem H: Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. Journal of Neuro-Oncology, 74(2);135-140, 2005. (PubMed)
Lesniak MS, Kelleher E, Pardoll DM, and Cui Y: Targeting gene therapy to antigen presenting cells in the CNS using hematopoietic stem cells. Neurol Research, 27(8):820-827, 2005. (PubMed)
Velicu S, Han Y, Ulasov I, Gajewski T, Lesniak MS: Cross-priming of T cell to intracranial tumor antigens fails in the effector phase but can be augmented with local immunotherapy. Journal of Neuroimmunology,174(1-2):74-81, 2006. (PubMed)
Ulasov IV, Tyler MA, Zeng S, Han Y, and Lesniak MS: CD46 represents a target for adenoviral gene therapy of malignant glioma. Human Gene Therapy, 17(5):556-64, 2006. (PubMed)
El Andaloussi A, Lesniak MS: An increase in CD4+CD25+Foxp3+ regulatory T cells in tumor-infiltrating lymphocyte of human glioblastoma. Neuro-Oncology, 8(3):234-43, 2006. (PubMed)
El Andaloussi A, Han Y, Lesniak MS: Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. Journal of Neurosurgery, 105:430-437, 2006. (PubMed)
Tyler MA, Ulasov IV, Borovjagin A, Sonabend A, Khramtsov A, Curiel DT, and Lesniak MS: Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber modified adenovirus. Molecular Cancer Therapeutics, 5(9):2408-16, 2006. (PubMed)
El Andaloussi A, Sonabend A, Han Y, and Lesniak MS: Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia, 54(6):526-35, 2006. (PubMed)
Zheng S, Ulasov IV, Tyler MA, Zhu ZB, and Lesniak MS. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. Journal of Gene Medicine, 9(3):151-160, 2007. (PubMed)
Ulasov IV, Tyler MA, Han Y, Glasgow JN, and Lesniak MS. A novel recombinant adenoviral vector that targets the IL13alpha2 receptor permits effective gene transfer to malignant glioma. Human Gene Therapy 18(2):118-29, 2007. (Cover Article) (PubMed)
Ulasov IV, Rivera AA, Sonabend AM, Wang M, Zhu ZB, and Lesniak MS: Evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biology and Therapy. May 3, 6(5): 679-685, 2007. (PubMed)
El Andaloussi A and Lesniak MS: CD4+CD25+FoxP3+ T cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. Journal of Neuro-Oncology, 83(2): 145-52, 2007. (PubMed)
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Khramtsov A, Curiel DT, Lesniak MS: A survivin-driven and fiber modified adenovirus exhibits potent anti-tumor activity in established intracranial glioma. Human Gene Therapy, 18:589-602, 2007. (PubMed)
Ulasov IV, Rivera AA, Nettelbeck DM, Mathis MJ, Rivera LB, Wang M, Curiel DT, Douglas JT, Lesniak MS. Oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. International Journal of Oncology, 31(5):1177-85, 2007. (PubMed)
Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H, Matar MM, Fewell JG, Anwer K, and Lesniak MS. A safety and efficacy study of local delivery of IL-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 19(2): 133-142, 2008. (PubMed)
Sonabend AM, Ulasov IV, Rivera AA, Mathis JM, and Lesniak MS. Mesenchymal stem effectively deliver an oncolytic adenoviruses to malignant gliomas. Stem Cells, In press.
